RE:RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024As requested, when I wrote that Big Pharma is interested in entering into M&A deals with corporate partners possessing complimentary, innovative, and market-ready drug products approaching commercialization, and that acquisitions of those biotechs with these kind of drug products, is a major solution to the looming problem that Big Pharma is beginning to face, I am referencing ONCY's "platform drug" pelareorep which can be used in multiple cancers and is an effective near market-ready and complimentary solution to Big Pharma's current product pipeline and can preclude Big Pharma's looming problem of loss of market exclusivity and accompanying revenue decline, particularly if they fail to take the appropriate M&A actions to mitigate the impending damage to their product pipelines.